Determining the methylation status of select genomic regions by targeted NGS is now possible using QIAGEN’s recently launched QIAseq Targeted Methyl Panels. This approach combines the advantages of QIAseq targeted sequencing technology, while avoiding many of the challenges associated with both whole genome and reduced representation bisulfite sequencing. These QIAseq advantages include increased NGS library uniformity, higher levels of sensitivity, faster workflows and the ability to readily customize panels to target methylation regions of interest.

In this webinar, we will describe additional aspects of our Sample to Insight solution, focusing on the analysis and visualization of targeted methyl panel data, using QIAGEN CLC Genomics Workbench software. The application contains a wide array of capabilities for the analysis of NGS methylation data. Ready-to-use workflows specific for QIAseq Targeted Methyl Panels allow you to quickly initiate analyses. Extensive flexibility regarding parameter choices allow you to customize these workflows for specific needs. We will demonstrate the software to show these and other key features.

By attending, you will learn how to: 

  • Process QIAseq Targeted Methyl Panels through the workflow
  • Set up the QIAGEN CLC Genomics Workbench for methylation data analysis
  • Extend the application tool set using the Biomedical Genomics Analysis plugin
  • Use specific workflows and tools for methylation data analysis
  • Inspect results and customize workflows to specific needs
About the speaker
Leif Schauser, Ph.D., Director Product Management Genome Analysis, Bioinformatics
Leif Schauser holds a Ph.D. in Plant Molecular Genetics from Aarhus University, Denmark. He did his postdoctoral training in Norwich, UK, before working as a professor in Bioinformatics at Aarhus University. In 2013 Leif joined CLC bio, just before its acquisition by QIAGEN.
Ioanna Andreou, Ph.D., Associate Director, NGS Application Development
Dr. Ioanna Andreou is an associate director at QIAGEN and is responsible for developing technologies for NGS applications. Dr. Andreou received her Ph.D. from the University of Freiburg, focusing on early cancer detection based on autoimmune response. She joined QIAGEN after a postdoctoral fellowship at the University of Cologne in 2002.
Date of recording:Friday, July 10, 2020
Duration:50 minutes
Next Generation Sequencing
Liquid Biopsy